© 2024 Foresight Diagnostics. All Rights Reserved.

Join our speakers

Webinar abstract

During this webinar, Dr. David Kurtz (Stanford University), Dr. Ryan Lynch (University of Washington) and Lara Stepan (Bristol Myers Squibb) will present results from recently presented studies demonstrating the superior prognostic utility of ctDNA for response assessment compared to PET/CT, particularly in B-cell lymphomas. Data summaries will include:

Thursday, March 7, 2024 at 1:00 pm ET (10:00 am PT)

Rethinking therapeutic response assessment in clinical trials using ultra-sensitive ctDNA

 New data and promising applications

  • MRD measurements at most time points before, during, and at the end of treatment were significantly more prognostic than PET/CT.
  • ctDNA measurement enabled end-of-treatment (EOT) response assessment 12 months earlier than using PET/CT-based PFS alone.
  • Improving the limit of detection (LOD) for ctDNA-MRD down to 1 in 1,000,000 improves prediction of clinical outcomes across multiple timepoints.

The discussion will continue with applications of earlier response assessment by ctDNA in clinical development, including use as surrogate endpoint to measure response in conjunction with PET/CT and as a biomarker to stop, start, or modify treatment cycles and regimens. The webinar will conclude with audience Q&A.

Krystal Brown is the Senior Director of Medical Affairs at Foresight Diagnostics. Krystal received her PhD in Chemistry from the University of Utah and has been working in molecular diagnostics for about 10 years. Krystal has been part of clinical strategy development and execution for many molecular diagnostics in Oncology, including germline tests, tissue-based prognostic tests, and liquid biopsy tests. At Foresight, she drives the clinical evidence generation strategy, including study planning, execution, and publication.

Krystal Brown, PhD

Sr Director of Medical Affairs, Foresight Diagnostics

David Kurtz (M.D./Ph.D.) is a co-founder of Foresight Diagnostics and an Assistant Professor of Medicine (Oncology) at Stanford University. His research focuses on developing and translating methods to detect, monitor, and treat hematologic malignancies. To accomplish this, Dr. Kurtz works at the intersection of molecular biology, cancer genomics, and bioengineering to develop the next generation of cancer diagnostics. Along with Dr. Alizadeh, Dr. Kurtz was one of the earliest investigators to explore the utility of tumor-derived cell-free DNA in lymphomas. He has applied multiple methodologies to the detection of cell-free DNA in lymphomas, with a focus on improving the clinical utility and analytical sensitivity of these methods. Clinically, Dr. Kurtz is a medical oncologist who specializes in the treatment of non-Hodgkin lymphomas. His research program also focuses on the clinical translation of NGS tools and computational approaches for improving patient care for patients with all types of cancer.

David Kurtz, MD, PhD

Co-founder, Foresight Diagnostics; Assistant Professor of Medicine, Stanford University

Dr. Ryan Lynch is a hematologist-oncologist at Fred Hutchinson Cancer Center who specializes in treating patients with a wide variety of lymphomas, including Hodgkin lymphoma, diffuse large B-cell lymphoma, other high-grade B-cell lymphomas. His research interests include clinical trials that optimize the use of novel agents for the treatment of Hodgkin lymphoma as well as non-Hodgkin lymphomas. This includes several research collaborations that are examining the role of minimal residual disease testing in the management of Hodgkin and non-
Hodgkin lymphomas.

Ryan Lynch, MD

Associate Professor, University of Washington School of Medicine;
Associate Professor, Clinical Research Division at Fred Hutchinson Cancer Center

Lara Stepan is a Senior Principal Translational Research Scientist in the Cancer Immunology and Cell Therapy Thematic Research Center at Bristol Myers Squibb at the Seattle, Washington location. In her role, Lara is a lead translational scientist supporting both early and late-stage CAR T cell and bi-specific antibody clinical studies and programs developed to treat patients with hematological malignancies or solid tumors. Most recently, Lara has been supporting Breyanzi development and approval in 2L/3L+ LBCL indications. Part of her role is to develop and implement translational research biomarker plans into clinical trial designs to deliver pharmacodynamic and predictive biomarker insights to accelerate clinical and pipeline development. Throughout her career her research has focused on immuno-oncology drug discovery, validation, and development. Prior to joining BMS her research was laboratory-based working for several pioneering biopharmaceutical companies including Immunex, Targeted Genetics, Dendreon, and Amgen. Lara received her B.S. in cell and molecular biology from the University of Washington. Her key areas of interest include oncology, immunology, cellular therapy, and circulating tumor DNA.

Lara Stepan

Senior Principal Scientist, Translational Research, Immuno-Oncology and Cellular Therapy

Want to learn more about ctDNA endpoints?

Explore PhasED-Seq →